JMH
AKBA icon

J.M. Hartwell’s Akebia Therapeutics AKBA Stock Holding History

J.M. Hartwell’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-10,000
Closed -$197K – 79
2017
Q3 		$197K Hold
10,000
– – 0.04% 82
2017
Q2 		$144K Buy
+10,000
New +$127K 0.03% 81

Other funds holding AKBA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

J.M. Hartwell's AKBA Position: Q4 2017 in Review

J.M. Hartwell sold out of Akebia Therapeutics (AKBA) in Q4 2017, closing a stake of 10,000 shares — an estimated $197K sold.

J.M. Hartwell first reported a position in AKBA in Q2 2017 and held it in 2 quarters. The position peaked at $197K in Q3 2017. 132 funds tracked by Wall St. Rank hold AKBA as of Q4 2017.

  • J.M. Hartwell reported no remaining Akebia Therapeutics position as of Q4 2017 after selling out during the quarter.
  • J.M. Hartwell sold 10,000 Akebia Therapeutics shares in Q4 2017, an estimated $197K.
  • J.M. Hartwell first reported a position in Akebia Therapeutics in Q2 2017 and held it in 2 quarters.
  • J.M. Hartwell's Akebia Therapeutics position peaked at $197K in Q3 2017.
  • 132 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q4 2017.

Based on J.M. Hartwell's 13F filing for Q4 2017, filed 22 Jan 2018.